Leucine-rich repeat 2 of human Toll-like receptor 4 contains the binding site for inhibitory monoclonal antibodies

FEBS Letters

Volumn 589, Issue 24, 2015, Pages 3893-3898

  Tsukamoto, Hiroki ^a,b   Ukai, Ippo ^a   Yamagata, Yuki ^a   Takeuchi, Shino ^a   Kubota, Kanae ^a   Kozakai, Sao ^a   Suzuki, Naoto ^a   Kimoto, Masao ^b   Tomioka, Yoshihisa ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

Epitope; Inhibitory monoclonal antibody; Lipopolysaccharide; MD 2; Toll like receptor 4

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; EPITOPE; LEUCINE RICH REPEAT KINASE 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HT52; PHENYLALANINE; PROLINE; PROTEIN MD 2; SERINE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; LEUCINE; TLR4 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CROSS REACTION; DRUG DESIGN; DRUG TARGETING; MOUSE; NONHUMAN; PRIORITY JOURNAL; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; CHEMISTRY; EPITOPE MAPPING; HUMAN; IMMUNIZATION; IMMUNOLOGY; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES; EPITOPE MAPPING; HUMANS; IMMUNIZATION; LEUCINE; MICE; MOLECULAR SEQUENCE DATA; REPETITIVE SEQUENCES, AMINO ACID; TOLL-LIKE RECEPTOR 4;

EID: 84959489978     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2015.11.018     Document Type: Article

References (23)

1. K. Hoshino, O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa, Y. Takeda, K. Takeda, S. Akira, Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol., 162, (1999), 3749-3752.
2. H. Tsukamoto, K. Fukudome, S. Takao, N. Tsuneyoshi, M. Kimoto, Lipopolysaccharide-binding protein-mediated Toll-like receptor 4 dimerization enables rapid signal transduction against lipopolysaccharide stimulation on membrane-associated CD14-expressing cells. Int. Immunol., 22, (2010), 271-280.
3. H. Tsukamoto, K. Fukudome, S. Takao, N. Tsuneyoshi, S. Ohta, Y. Nagai, H. Ihara, K. Miyake, Y. Ikeda, M. Kimoto, Reduced surface expression of TLR4 by a V254I point mutation accounts for the low lipopolysaccharide responder phenotype of BALB/c B cells. J. Immunol., 190, (2013), 195-204.
4. N.M. Rachmawati, K. Fukudome, N. Tsuneyoshi, U. Bahrun, H. Tsukamoto, T. Yanagibashi, Y. Nagai, K. Takatsu, S. Ohta, M. Kimoto, Inhibition of antibody production in vivo by pre-stimulation of Toll-like receptor 4 before antigen priming is caused by defective B-cell priming and not impairment in antigen presentation. Int. Immunol., 25, (2013), 117-128.
5. H. Tsukamoto, K. Fukudome, S. Takao, N. Tsuneyoshi, H. Ihara, Y. Ikeda, M. Kimoto, Multiple potential regulatory sites of TLR4 activation induced by LPS as revealed by novel inhibitory human TLR4 mAbs. Int. Immunol., 24, (2012), 495-506.
6. A. Visintin, K.A. Halmen, E. Latz, B.G. Monks, D.T. Golenbock, Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J. Immunol., 175, (2005), 6465-6472.
7. M. Mullarkey, J.R. Rose, J. Bristol, T. Kawata, A. Kimura, S. Kobayashi, M. Przetak, J. Chow, F. Gusovsky, W.J. Christ, D.P. Rossignol, Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther., 304, (2003), 1093-1102.
8. F. Peri, M. Piazza, Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists. Biotechnol. Adv., 30, (2012), 251-260.
9. S.H. Park, N.D. Kim, J.K. Jung, C.K. Lee, S.B. Han, Y. Kim, Myeloid differentiation 2 as a therapeutic target of inflammatory disorders. Pharmacol. Ther., 133, (2012), 291-298.
10. H.M. Kim, B.S. Park, J.I. Kim, S.E. Kim, J. Lee, S.C. Oh, P. Enkhbayar, N. Matsushima, H. Lee, O.J. Yoo, J.O. Lee, Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell, 130, (2007), 906-917.
11. H. Tsukamoto, H. Ihara, R. Ito, I. Ukai, N. Suzuki, M. Kimoto, Y. Tomioka, Y. Ikeda, MD-2-dependent human Toll-like receptor 4 monoclonal antibodies detect extracellular association of Toll-like receptor 4 with extrinsic soluble MD-2 on the cell surface. Biochem. Biophys. Res. Commun., 440, (2013), 31-36.
12. R. Shimazu, S. Akashi, H. Ogata, Y. Nagai, K. Fukudome, K. Miyake, M. Kimoto, MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med., 189, (1999), 1777-1782.
13. B.S. Park, D.H. Song, H.M. Kim, B.S. Choi, H. Lee, J.O. Lee, The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature, 458, (2009), 1191-1195.
14. S. Saitoh, S. Akashi, T. Yamada, N. Tanimura, M. Kobayashi, K. Konno, F. Matsumoto, K. Fukase, S. Kusumoto, Y. Nagai, Y. Kusumoto, A. Kosugi, K. Miyake, Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int. Immunol., 16, (2004), 961-969.
15. S.M. Opal, P.F. Laterre, B. Francois, S.P. LaRosa, D.C. Angus, J.P. Mira, X. Wittebole, T. Dugernier, D. Perrotin, M. Tidswell, L. Jauregui, K. Krell, J. Pachl, T. Takahashi, C. Peckelsen, E. Cordasco, C.S. Chang, S. Oeyen, N. Aikawa, T. Maruyama, R. Schein, A.C. Kalil, M. Van Nuffelen, M. Lynn, D.P. Rossignol, J. Gogate, M.B. Roberts, J.L. Wheeler, J.L. Vincent, A.S. Group, Effect of Eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA, 309, (2013), 1154-1162.
16. S. Akashi, S. Saitoh, Y. Wakabayashi, T. Kikuchi, N. Takamura, Y. Nagai, Y. Kusumoto, K. Fukase, S. Kusumoto, Y. Adachi, A. Kosugi, K. Miyake, Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J. Exp. Med., 198, (2003), 1035-1042.
17. A. Shimamoto, A.J. Chong, M. Yada, S. Shomura, H. Takayama, A.J. Fleisig, M.L. Agnew, C.R. Hampton, C.L. Rothnie, D.J. Spring, T.H. Pohlman, H. Shimpo, E.D. Verrier, Inhibition of Toll-like receptor 4 with Eritoran attenuates myocardial ischemia-reperfusion injury. Circulation, 114, (2006), I270-274.
18. W.K. den Dekker, C. Cheng, G. Pasterkamp, H.J. Duckers, Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis, 209, (2010), 314-320.
19. H. Yang, H. Wang, Z. Ju, A.A. Ragab, P. Lundback, W. Long, S.I. Valdes-Ferrer, M. He, J.P. Pribis, J. Li, B. Lu, D. Gero, C. Szabo, D.J. Antoine, H.E. Harris, D.T. Golenbock, J. Meng, J. Roth, S.S. Chavan, U. Andersson, T.R. Billiar, K.J. Tracey, Y. Al-Abed, MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J. Exp. Med., 212, (2015), 5-14.
20. J.S. Lee, J.Y. Lee, M.Y. Lee, D.H. Hwang, H.S. Youn, Acrolein with an alpha, beta-unsaturated carbonyl group inhibits LPS-induced homodimerization of Toll-like receptor 4. Mol. Cells, 25, (2008), 253-257.
21. M. Mancek-Keber, H. Gradisar, M. Inigo Pestana, G. Martinez de Tejada, R. Jerala, Free thiol group of MD-2 as the target for inhibition of the lipopolysaccharide-induced cell activation. J. Biol. Chem., 284, (2009), 19493-19500.
22. M.D. Neal, H. Jia, B. Eyer, M. Good, C.J. Guerriero, C.P. Sodhi, A. Afrazi, T. Prindle Jr., C. Ma, M. Branca, J. Ozolek, J.L. Brodsky, P. Wipf, D.J. Hackam, Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors. PLoS ONE, 8, (2013), e65779 -
23. E. Roh, H.S. Lee, J.A. Kwak, J.T. Hong, S.Y. Nam, S.H. Jung, J.Y. Lee, N.D. Kim, S.B. Han, Y. Kim, MD-2 as the target of nonlipid chalcone in the inhibition of endotoxin LPS-induced TLR4 activity. J. Infect. Dis., 203, (2011), 1012-1020.